CO2019007839A2 - Composiciones y métodos para inhibir la acción de la arginasa - Google Patents

Composiciones y métodos para inhibir la acción de la arginasa

Info

Publication number
CO2019007839A2
CO2019007839A2 CONC2019/0007839A CO2019007839A CO2019007839A2 CO 2019007839 A2 CO2019007839 A2 CO 2019007839A2 CO 2019007839 A CO2019007839 A CO 2019007839A CO 2019007839 A2 CO2019007839 A2 CO 2019007839A2
Authority
CO
Colombia
Prior art keywords
arginase
methods
compositions
inhibiting
action
Prior art date
Application number
CONC2019/0007839A
Other languages
English (en)
Inventor
Eric B Sjogren
Jim Li
Lijing Chen
Roland J Billedeau
Timothy F Stanton
Zandt Michael Van
Darren Whitehouse
Gunnar E Jagdmann Jr
Lene Raunkjaer Petersen
Francesco Parlati
Matthew I Gross
Original Assignee
Calithera Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60972528&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2019007839(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Calithera Biosciences Inc filed Critical Calithera Biosciences Inc
Publication of CO2019007839A2 publication Critical patent/CO2019007839A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La descripción consiste en una clase novedosa de compuestos que muestran actividad inhibitoria de la arginasa, y composiciones farmaceúticas que incluyen los compuestos de la descripción. En la presente también se ofrecen los métodos de tratamiento contra el cáncer con los inhibidores de la arginasa de la descripción.
CONC2019/0007839A 2016-12-22 2019-07-22 Composiciones y métodos para inhibir la acción de la arginasa CO2019007839A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662438092P 2016-12-22 2016-12-22
US201662439614P 2016-12-28 2016-12-28
PCT/US2017/068307 WO2018119440A1 (en) 2016-12-22 2017-12-22 Compositions and methods for inhibiting arginase activity

Publications (1)

Publication Number Publication Date
CO2019007839A2 true CO2019007839A2 (es) 2019-10-21

Family

ID=60972528

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0007839A CO2019007839A2 (es) 2016-12-22 2019-07-22 Composiciones y métodos para inhibir la acción de la arginasa

Country Status (32)

Country Link
US (4) US10287303B2 (es)
EP (2) EP3559009B1 (es)
JP (2) JP7018949B2 (es)
KR (1) KR102579849B1 (es)
CN (2) CN114989205A (es)
AU (2) AU2017382405B2 (es)
BR (1) BR112019012589B1 (es)
CA (1) CA3046987A1 (es)
CL (1) CL2019001711A1 (es)
CO (1) CO2019007839A2 (es)
CR (1) CR20190339A (es)
CY (1) CY1124483T1 (es)
DK (2) DK3559009T3 (es)
EC (1) ECSP19045511A (es)
ES (1) ES2881395T3 (es)
HR (1) HRP20210848T1 (es)
HU (1) HUE054272T2 (es)
IL (2) IL292677A (es)
LT (1) LT3559009T (es)
MD (1) MD3559009T2 (es)
MX (2) MX2019007471A (es)
MY (1) MY197478A (es)
NZ (1) NZ754364A (es)
PE (1) PE20191541A1 (es)
PH (1) PH12019501396A1 (es)
PL (1) PL3559009T3 (es)
PT (1) PT3559009T (es)
RS (1) RS61996B1 (es)
SG (2) SG10201911243WA (es)
SI (1) SI3559009T1 (es)
TW (1) TWI818902B (es)
WO (1) WO2018119440A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2568680T3 (es) 2010-10-26 2016-05-03 Mars, Incorporated Boratos como inhibidores de arginasa
EP3365340B1 (en) 2015-10-19 2022-08-10 Incyte Corporation Heterocyclic compounds as immunomodulators
MX2018006207A (es) 2015-11-19 2018-09-05 Incyte Corp Compuestos heterociclicos como inmunomoduladores.
LT3394033T (lt) 2015-12-22 2021-03-10 Incyte Corporation Heterocikliniai junginiai, kaip imunomoduliatoriai
TW201808950A (zh) 2016-05-06 2018-03-16 英塞特公司 作為免疫調節劑之雜環化合物
US20170342060A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
EP4137489A1 (en) 2016-06-20 2023-02-22 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018013789A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
MA46045A (fr) 2016-08-29 2021-04-28 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
HRP20221216T1 (hr) * 2016-12-22 2022-12-23 Incyte Corporation Derivati tetrahidro imidazo[4,5-c]piridina kao induktori internalizacije pd-l1
MX2019007416A (es) 2016-12-22 2019-12-11 Incyte Corp Derivados de benzooxazol como inmunomoduladores.
WO2018119221A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
DK3559009T3 (da) * 2016-12-22 2021-05-03 Calithera Biosciences Inc Sammensætninger og metoder til inhibition af arginaseaktivitet
US20180179201A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
CN108322295B (zh) 2017-01-17 2021-12-24 维沃移动通信有限公司 一种边带信息的发送方法、接收方法、发送端和接收端
UY38096A (es) 2018-02-17 2019-07-31 Astrazeneca Ab Inhibidores de arginasa y sus métodos de uso
WO2019186497A1 (en) 2018-03-29 2019-10-03 Oncoarendi Therapeutics S.A. Dipeptide piperidine derivatives
RS64188B1 (sr) 2018-05-11 2023-06-30 Incyte Corp Tetrahidro-imidazo[4,5-c]piridin derivati kao pd-l1 imunomodulatori
KR20210049120A (ko) 2018-08-22 2021-05-04 아스트라제네카 아베 아르기나제 저해제 및 이의 사용 방법
WO2020131598A1 (en) * 2018-12-18 2020-06-25 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
CR20210463A (es) * 2019-02-08 2021-10-15 Astrazeneca Ab Inhibidores de arginasa y métodos de uso de estos
US11753406B2 (en) 2019-08-09 2023-09-12 Incyte Corporation Salts of a PD-1/PD-L1 inhibitor
CN110759843A (zh) * 2019-09-30 2020-02-07 东北师范大学 一种氟叠氮取代的四元杂环化合物的制备和应用
CN110734456A (zh) * 2019-11-06 2020-01-31 南京谷睿生物科技有限公司 一种化合物及其制备方法和医药上的应用
KR20220101664A (ko) 2019-11-11 2022-07-19 인사이트 코포레이션 Pd-1/pd-l1 억제제의 염 및 결정질 형태
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
EP4175719A1 (en) 2020-07-02 2023-05-10 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
US20220041630A1 (en) * 2020-07-17 2022-02-10 Incyte Corporation Processes for the preparation of arginase inhibitors and their synthetic intermediates
WO2022046989A1 (en) 2020-08-27 2022-03-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor
KR20230117573A (ko) 2020-11-06 2023-08-08 인사이트 코포레이션 Pd-1 및 pd-l1 억제제, 및 이의 염 및 결정형의 제조 방법
CN112387262B (zh) * 2020-11-10 2021-12-07 泰州学院 一种基于光催化交联蛋白的手性固定相的制备方法、手性固定相及应用
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
TW202228720A (zh) 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法
EP4298099A1 (en) 2021-02-25 2024-01-03 Incyte Corporation Spirocyclic lactams as jak2 v617f inhibitors
WO2023133505A2 (en) * 2022-01-07 2023-07-13 The Trustees Of Columbia University In The City Of New York Inhibition of kynurenine synthesis and/or signaling to treat leukemia and myelodysplasia
WO2023178285A1 (en) 2022-03-17 2023-09-21 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
CN1229110C (zh) 1997-07-29 2005-11-30 阿尔康实验室公司 含半乳甘露聚糖聚合物和硼酸盐的眼用组合物
CA2305703A1 (en) 1997-10-10 1999-04-22 David W. Christianson Compositions and methods for inhibiting arginase activity
EP1051167A1 (en) 1998-01-29 2000-11-15 Sepracor, Inc. Pharmaceutical uses of optically pure (-) -bupropion
US20040063666A1 (en) 1998-10-09 2004-04-01 David Christianson Compositions for inhibiting arginase activity
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
EP1299398A1 (en) 2000-07-06 2003-04-09 Fal Diagnostics Methods and kits for the detection of arginine compounds
CA2431080A1 (en) 2003-06-02 2004-12-02 Catherine Adele O'brien Enhancement of anticancer immunity through inhibition of arginase
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
DK1654002T4 (da) 2003-08-07 2014-02-17 Allergan Inc Sammensætninger til fremføring af terapeutiske midler til øjnene
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
EP1915143A4 (en) 2005-07-01 2009-11-11 Univ Johns Hopkins ARGINASE II: TARGET TREATMENT FOR THE AGING HEART AND HEART FAILURE
WO2007095050A2 (en) 2006-02-09 2007-08-23 Incyte Corporation N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase
US20080119491A1 (en) 2006-09-19 2008-05-22 Incyte Corporation Amidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
US20080146624A1 (en) 2006-09-19 2008-06-19 Incyte Corporation Amidines as modulators of indoleamine 2,3-dioxygenase
CA2663057C (en) 2006-09-19 2015-12-08 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
US20080182882A1 (en) 2006-11-08 2008-07-31 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
SI3034075T1 (sl) 2006-11-22 2018-12-31 Incyte Holdings Corporation Imidazotriazini in imidazopirimidini kot inhibitorji kinaze
WO2009073620A2 (en) 2007-11-30 2009-06-11 Newlink Genetics Ido inhibitors
EP2291187B1 (en) 2008-04-24 2018-08-15 Newlink Genetics Corporation Ido inhibitors
PT2824100T (pt) 2008-07-08 2018-05-10 Incyte Holdings Corp 1,2,5-oxadiazoles como inibidores da indoleamina 2,3-dioxigenase
DK2389352T3 (da) 2009-01-26 2019-07-29 Univ Pennsylvania Arginaseinhibitorer og anvendelsesfremgangsmåder
CA2785898C (en) 2009-12-31 2018-07-03 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
EP2547366A4 (en) 2010-03-18 2013-08-07 Univ Colorado State Res Found INHIBITING AGENTS OF SUPPRESSIVE MYELOID CELLS
RU2586219C2 (ru) 2010-04-22 2016-06-10 Марс, Инкорпорейтед Ингибиторы аргиназы и их терапевтические применения
ES2563319T3 (es) 2010-04-24 2016-03-14 Viamet Pharmaceuticals, Inc. Compuestos inhibidores de metaloenzimas
PL2603514T3 (pl) 2010-08-10 2019-04-30 Rempex Pharmaceuticals Inc Cykliczne pochodne estrowe kwasu boronowego oraz ich zastosowania terapeutyczne
CA2809331C (en) 2010-08-27 2018-09-25 Merck Patent Gmbh Triazolopyrazine derivatives
ES2568680T3 (es) 2010-10-26 2016-05-03 Mars, Incorporated Boratos como inhibidores de arginasa
US9056855B2 (en) 2010-10-28 2015-06-16 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
ES2703498T3 (es) 2010-11-13 2019-03-11 Innocrin Pharmaceuticals Inc 1-(6,7-Bis(difluorometoxi)naftalen-2-il)-2-metil-1-(1H-1,2,3-triazol-4-il)propan-1-ol como inhibidor de CYP17 para el tratamiento de enfermedades dependientes de andrógenos como el cáncer de próstata
WO2012082746A2 (en) 2010-12-13 2012-06-21 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
EP2658580A4 (en) * 2010-12-31 2014-07-23 Corridor Pharmaceuticals Inc ARGINE STARTER AND USE METHOD
NO2694640T3 (es) 2011-04-15 2018-03-17
AU2012273166A1 (en) 2011-06-19 2014-01-23 Viamet Pharmaceuticals (NC), Inc. Metalloenzyme inhibitor compounds
BR122020013521B1 (pt) 2011-06-19 2021-05-25 Viamet Pharmaceuticals (NC), Inc compostos inibidores de metaloenzima
US8883797B2 (en) 2011-06-23 2014-11-11 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
US9150527B2 (en) 2011-08-30 2015-10-06 Innocrin Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
AU2012326109A1 (en) 2011-10-19 2014-05-29 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
AU2012325909B2 (en) * 2011-10-20 2016-06-09 Glaxosmithkline Llc Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
BR112014013963B1 (pt) 2011-12-11 2021-06-22 Nqp 1598, Ltd Compostos inibidores de metaloenzimas, composições compreendendo os ditos compostos, uso terapêutico dos mesmos e métodos para inibir a atividade de metaloenzimas e para tratar ou prevenir o crescimento de fungos em plantas
IN2014DN06792A (es) 2012-01-20 2015-05-22 Viamet Pharmaceuticals Inc
MX2014008864A (es) 2012-01-28 2014-12-15 Merck Patent Gmbh Derivados de triazolo[4,5-d]pirimidina.
US9120804B2 (en) 2012-02-21 2015-09-01 Merck Patent Gmbh 8-substituted 2-amino-[1,2,4] triazolo [1, 5-A] pyrazines as Syk tryrosine kinase inhibitors and GCN2 serin kinase inhibitors
US9073944B2 (en) 2012-02-21 2015-07-07 Merck Patent Gmbh Cyclic diaminopyrimidine derivatives
CN104159901B (zh) 2012-03-07 2016-10-26 默克专利股份公司 三唑并吡嗪衍生物
EP2852598B3 (en) 2012-04-18 2016-10-19 Mars, Incorporated Ring constrained analogs as arginase inhibitors
AU2013301865B2 (en) 2012-08-07 2017-08-17 Merck Patent Gmbh Pyridopyrimidine derivatives as protein kinase inhibitors
EP2894981B1 (en) 2012-09-12 2019-12-04 Dow AgroSciences LLC Metalloenzyme inhibitor compounds
EP2948450A4 (en) 2013-01-28 2016-11-09 Viamet Pharmaceuticals Inc METALLOENZYMINHIBITORVERBINDUNGEN
CA2903903C (en) 2013-03-05 2021-05-04 Merck Patent Gmbh Triazolo[4,5-d]pyrimidine derivatives for the treatment of diseases such as cancer
AU2014224976B2 (en) 2013-03-05 2017-09-28 Merck Patent Gmbh 9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents
EP2976332B1 (en) 2013-03-14 2018-01-31 Newlink Genetics Corporation Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization.
HUE039473T2 (hu) 2013-03-14 2019-01-28 Curadev Pharma Private Ltd Kinurenin útvonal inhibitorok
WO2014141110A2 (en) 2013-03-14 2014-09-18 Curadev Pharma Pvt. Ltd. Aminonitriles as kynurenine pathway inhibitors
JP6313416B2 (ja) 2013-03-15 2018-04-18 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｉｄｏ阻害剤
WO2014150646A1 (en) 2013-03-15 2014-09-25 Bristol-Myers Squibb Company Ido inhibitors
CA2911259A1 (en) 2013-05-06 2014-11-13 Merck Patent Gmbh Macrocycles as kinase inhibitors
US9447073B2 (en) 2013-05-28 2016-09-20 Viamet Pharmaceuticals, Inc. Fungicidal compositions
ES2719327T3 (es) 2013-07-01 2019-07-09 Bristol Myers Squibb Co Inhibidores de IDO
CN105517999B (zh) 2013-07-11 2019-06-28 百时美施贵宝公司 Ido抑制剂
US10821178B2 (en) 2013-07-29 2020-11-03 Board Of Regents Of The University Of Nebraska Methods of treating biofilm infections comprising administering inhibitors of myeloid-derived suppressor cells
CA2921199A1 (en) 2013-08-27 2015-03-05 Bristol-Myers Squibb Company Ido inhibitors
CN105848680A (zh) 2013-10-25 2016-08-10 药品循环有限责任公司 使用布鲁顿酪氨酸激酶抑制剂和免疫疗法的治疗
CR20160252A (es) 2013-11-08 2016-09-19 Incyte Holdings Corp Proceso para la sintesis de un inhibidor de indolamina 2,3-dioxigenasa
NZ722891A (en) 2014-02-04 2021-07-30 Incyte Corp Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
CA2945674A1 (en) 2014-04-15 2015-10-22 Dow Agrosciences Llc Metalloenzyme inhibitor compounds as fungicides
WO2015160664A1 (en) 2014-04-15 2015-10-22 Dow Agrosciences Llc Metalloenzyme inhibitor compounds as fungicides
JP2017525753A (ja) 2014-06-06 2017-09-07 フレクサス・バイオサイエンシーズ・インコーポレイテッドＦｌｅｘｕｓ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ． 免疫調節剤
TW201619133A (zh) 2014-08-21 2016-06-01 裘拉德製藥私人有限公司 新穎亞氨腈（ｉｍｉｎｏｎｉｔｒｉｌｅ）衍生物
ES2751602T3 (es) 2014-09-05 2020-04-01 Merck Patent Gmbh Compuestos diaza y triaza tricíclicos sustituidos con (1-fluoro-ciclohex-1-il)-etilo como antagonistas de la indol-amina-2,3-dioxigenasa (ido) para el tratamiento del cáncer
CN105879030A (zh) 2014-09-30 2016-08-24 复旦大学 治疗肿瘤的增效药物复合物及其制备方法
GB201417369D0 (en) 2014-10-01 2014-11-12 Redx Pharma Ltd Compounds
WO2016057986A1 (en) 2014-10-10 2016-04-14 The Trustees Of Columbia University In The City Of New York Tandem epitope constructs for presentation of cd4 and cd8 epitopes and uses thereof
GB201418300D0 (en) 2014-10-15 2014-11-26 Redx Pharma Ltd Compounds
AR102537A1 (es) 2014-11-05 2017-03-08 Flexus Biosciences Inc Agentes inmunomoduladores
CN107205970A (zh) 2014-11-05 2017-09-26 弗莱塞斯生物科学公司 免疫调节剂
UY36390A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
US9586949B2 (en) 2015-02-09 2017-03-07 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
KR20170129896A (ko) 2015-03-20 2017-11-27 새미 오유 오피요 악성 신생물에 대한 수라민 및 아르기나아제 억제제의 용도
CN107660205B (zh) 2015-04-03 2021-08-27 因赛特公司 作为lsd1抑制剂的杂环化合物
SG11201708097SA (en) 2015-04-03 2017-10-30 Bristol Myers Squibb Co Inhibitors of indoleamine 2,3-dioxygenase for the treatment of cancer
CA2929850A1 (en) 2015-05-14 2016-11-14 Pfizer Inc. Combination therapies comprising a pyrrolidine-2,5-dione ido1 inhibitor
WO2016196890A1 (en) 2015-06-04 2016-12-08 Vtv Therapeutics Llc Inhibitors of hexokinase and methods of use thereof
JP2018520352A (ja) 2015-06-23 2018-07-26 カリセラ バイオサイエンシズ，インコーポレイテッド アルギナーゼ活性を阻害するための組成物および方法
KR20220118559A (ko) 2015-10-30 2022-08-25 칼리테라 바이오사이언시즈, 인코포레이티드 아르기닌 활성 억제용 조성물 및 방법
DK3559009T3 (da) * 2016-12-22 2021-05-03 Calithera Biosciences Inc Sammensætninger og metoder til inhibition af arginaseaktivitet

Also Published As

Publication number Publication date
EP3559009A1 (en) 2019-10-30
ES2881395T3 (es) 2021-11-29
CN110382508B (zh) 2022-08-02
CN110382508A (zh) 2019-10-25
AU2017382405B2 (en) 2021-12-16
IL267532A (en) 2019-08-29
EP3559009B1 (en) 2021-04-07
DK3559009T3 (da) 2021-05-03
JP2022066199A (ja) 2022-04-28
SG10201911243WA (en) 2020-02-27
PT3559009T (pt) 2021-05-04
SG10201911240PA (en) 2020-02-27
MX2020013649A (es) 2021-02-26
SI3559009T1 (sl) 2021-08-31
US10287303B2 (en) 2019-05-14
AU2017382405A1 (en) 2019-06-27
CR20190339A (es) 2020-01-10
PL3559009T3 (pl) 2021-10-25
US10597411B2 (en) 2020-03-24
WO2018119440A1 (en) 2018-06-28
HRP20210848T1 (hr) 2021-07-09
PE20191541A1 (es) 2019-10-23
DK3842442T3 (da) 2024-02-05
BR112019012589A2 (pt) 2019-11-19
AU2022201072A1 (en) 2022-03-10
BR112019012589B1 (pt) 2022-11-29
CY1124483T1 (el) 2022-07-22
HUE054272T2 (hu) 2021-09-28
US20180222926A1 (en) 2018-08-09
KR102579849B1 (ko) 2023-09-18
MX2019007471A (es) 2019-11-05
CN114989205A (zh) 2022-09-02
IL267532B (en) 2022-06-01
EP3842442A1 (en) 2021-06-30
IL292677A (en) 2022-07-01
US20210261573A1 (en) 2021-08-26
JP2020514271A (ja) 2020-05-21
US20190330244A1 (en) 2019-10-31
TWI818902B (zh) 2023-10-21
CL2019001711A1 (es) 2020-01-17
US20200339607A1 (en) 2020-10-29
CA3046987A1 (en) 2018-06-28
MY197478A (en) 2023-06-19
EP3842442B1 (en) 2023-11-01
KR20190119579A (ko) 2019-10-22
MD3559009T2 (ro) 2021-07-31
TW201828948A (zh) 2018-08-16
RS61996B1 (sr) 2021-07-30
ECSP19045511A (es) 2019-10-31
LT3559009T (lt) 2021-06-25
JP7018949B2 (ja) 2022-02-14
NZ754364A (en) 2023-04-28
PH12019501396A1 (en) 2019-12-02
US11021495B2 (en) 2021-06-01

Similar Documents

Publication Publication Date Title
CO2019007839A2 (es) Composiciones y métodos para inhibir la acción de la arginasa
ECSP18040250A (es) Composiciones y métodos para inhibir la actividad arginasa
CO2019011543A2 (es) Inhibidores de pd-1/pd-l1
CL2021000084A1 (es) Inhibidores de pd-1/pd-l1
CO2020009861A2 (es) Inhibidores pd-1/pd-l1
NI201600165A (es) Inhibidores de desmetilasa 1 específica a lisina
CL2018000429A1 (es) Moduladores de la expresión de kras
CL2017002786A1 (es) Referencia cruzada a solicitudes relacionadas
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
BR112018073328A2 (pt) combinação, composição farmacêutica, kit, método para tratamento de câncer, método para a redução de um nível de células, método para reduzir o nível de células, método para aumentar a atividade, método para aumentar a citotoxicidade
EA201591509A1 (ru) Ингибиторы cdc7
CO2018008846A2 (es) Derivados de carboxamida útiles como inhibidores de rsk
CO2017005038A2 (es) Composicones y métodos de tratamiento con profármacos de tizoxanida, un análogo o sal de la misma
BR112017000730A2 (pt) derivados de pirrolidinona como inibidores de metap-2
SA519410093B1 (ar) مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t
EA202191495A1 (ru) Композиции и способы ингибирования активности аргиназы
EA202191138A1 (ru) Композиции и способы для ингибирования активности аргиназы